Form 4: ImmuCell Director David Tomsche Acquires 10,000 Shares of Common Stock

Director David Tomsche purchased 10,000 shares of ImmuCell Corp common stock at $3.55 per share on August 22, 2024.

Summary

• On August 22, 2024, David Tomsche, a director of ImmuCell Corporation, acquired 10,000 shares of the company's common stock.
• The purchase price was $3.55 per share.
• Following the transaction, Tomsche directly owns 123,606 shares, which includes 6,987 shares held by immediate family members.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's future. However, the impact is moderate as it's a single transaction and the size is not exceptionally large relative to the director's existing holdings.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's view of the company's prospects. It can be compared to other insider transactions within the company and across the industry to gauge sentiment.

Comparison to Industry Standards

• Comparing Tomsche's purchase to other insider transactions in similar companies within the animal health industry could provide context.
• For example, if executives at companies like Zoetis or Elanco Animal Health are also increasing their holdings, it could signal a broader positive outlook for the sector.

Stakeholder Impact

• The stock purchase could positively influence shareholder sentiment.

Key Dates